REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Director/PDMR Shareholding

MaxCyteAnnouncement

30/03/2023 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230330:nRSd8160Ua&default-theme=true

RNS Number : 8160U  MaxCyte, Inc.  30 March 2023

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

PDMR Dealing

 

Gaithersburg, Maryland - 30 March 2023: MaxCyte Inc., (NASDAQ: MXCT; LSE:
MXCT), a leading, cell-engineering focused company providing enabling
platform technologies to advance the discovery, development, and
commercialization of next-generation cell therapeutics and to support
innovative, cell-based research, announces that on 29 March 2023 Richard
Douglas, Non-Executive Chairman of the Company, purchased 80,000 shares on the
open market of common stock in the Company ("Common Stock"). The 80,000 shares
of Common Stock were purchased at an average price of $4.3185 per Common
stock.

 

Following the purchase of Common Stock, Richard Douglas holds a total of
100,000 Common Stock representing approximately 0.1 percent of the issued
share capital of the Company. Richard Douglas holds a
further 158,500 options over Common Stock.

 

MaxCyte Contacts:

 

 US IR Adviser

 Gilmartin Group                               +1 415-937-5400

 David Deuchler, CFA                           ir@maxcyte.com (mailto:ir@maxcyte.com)

 Nominated Adviser and Joint Corporate Broker

 Panmure Gordon                                +44 (0)20 7886 2500

 Emma Earl / Freddy Crossley

 Corporate Broking

 Rupert Dearden

 UK IR Adviser                                 +44 (0)203 709 5700

 Consilium Strategic Communications            maxcyte@consilium-comms.com (mailto:maxcyte@consilium-comms.com)

 Mary-Jane Elliott

 Chris Welsh

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology, as
well as technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at maxcyte.com
(https://maxcyte.com/) and follow us on Twitter
(https://twitter.com/MaxCyte_info) and LinkedIn
(https://www.linkedin.com/company/maxcyte-inc-/) .

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Richard Douglas

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Chairman

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         MaxCyte Inc.

 b)   LEI                                                          54930053YHXULRFCU991

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Common Stock of $0.01 each

      Identification code                                          US57777K1060

 b)   Nature of the transaction                                    Purchase of common stock

 c)   Price(s) and volume(s)

                                                                                     Purchase Price(s) range  Volume(s)
                                                                                     $4.20-$4.35              80,000

 d)   Aggregated information

      - Aggregated volume                                          80,000

      - Price                                                      $4.3185

 e)   Date of the transaction                                      29 March 2023

 f)   Place of the transaction                                     USStock Exchange, Nasdaq

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEAFDEDLDDEFA